Elucidating the molecular basis of MSH2‐deficient tumors by combined germline and somatic analysis. Issue 7 (3rd July 2017)

• Record Type: Journal Article
• Authors: Vargas‐Parra, Gardenia M.; González‐Acosta, Maribel; Thompson, Bryony A.; Gómez, Carolina; Fernández, Anna; Dámaso, Estela; Pons, Tirso; Morak, Monika; del Valle, Jesús; Iglesias, Silvia; Velasco, Àngela; Solanes, Ares; Sanjuan, Xavier; Padilla, Natàlia; de la Cruz, Xavier; Valencia, Alfonso; Holinski‐Feder, Elke; Brunet, Joan; Feliubadaló, Lídia; Lázaro, Conxi; Navarro, Matilde; Pineda, Marta; Capellá, Gabriel
• Is Part Of: International journal of cancer. Volume 141:Issue 7(2017:Oct. 01)
• Page Start: 1365
• Page End: 1380
• Publication Date: 2017-07-03
• Subjects: Lynch syndrome -- Lynch‐like -- next‐generation sequencing -- mismatch repair‐deficiency -- methylation; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.30820
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : In a proportion of patients presenting mismatch repair (MMR)‐deficient tumors, no germline MMR mutations are identified, the so‐called Lynch‐like syndrome (LLS). Recently, MMR‐deficient tumors have been associated with germline mutations in POLE and MUTYH or double somatic MMR events. Our aim was to elucidate the molecular basis of MSH2‐deficient LS‐suspected cases using a comprehensive analysis of colorectal cancer (CRC)‐associated genes at germline and somatic level. Fifty‐eight probands harboring MSH2‐deficient tumors were included. Germline mutational analysis of MSH2 (including EPCAM deletions) and MSH6 was performed. Pathogenicity of MSH2 variants was assessed by RNA analysis and multifactorial likelihood calculations. MSH2 cDNA and methylation of MSH2 and MSH6 promoters were studied. Matched blood and tumor DNA were analyzed using a customized next generation sequencing panel. Thirty‐five individuals were carriers of pathogenic or probably pathogenic variants in MSH2 and EPCAM . Five patients harbored 4 different MSH2 variants of unknown significance (VUS) and one had 2 novel MSH6 promoter VUS. Pathogenicity assessment allowed the reclassification of the 4 MSH2 VUS and 6 probably pathogenic variants as pathogenic mutations, enabling a total of 40 LS diagnostics. Predicted pathogenic germline variants in BUB1, SETD2, FAN1 and MUTYH were identified in 5 cases. Three patients had double somatic hits in MSH2 or MSH6, and another 2 had somatic alterations in other MMR genes and/or proofreading polymerases. In conclusion, our comprehensive strategy combining germline and somatic mutational status of CRC‐associated genes by means of a subexome panel allows the elucidation of up to 86% of MSH2‐deficient suspected LS tumors. Abstract : What's new? Although Lynch syndrome is known as an inherited cancer syndrome causing colorectal and endometrial tumors at a young age, more than half of the affected individuals do not carry the expected germline mutations in mismatch repair genes. Here the authors comprehensively analyzed the germline and somatic mutational status of patients with suspected Lynch syndrome. They confirm marked heterogeneity in the underlying mutations and molecularly classified up to 86% of the cases, underscoring the need for a comprehensive analysis to allow meaningful genetic counseling and follow‐up.